Dermavant Sciences, a subsidiary of Roivant Sciences, is a biopharmaceutical company committed to fostering unprecedented change and unparalleled impact in immuno-dermatology. Our mission is to make healthier skin a reality for the millions of people around the world living with chronic skin conditions. That’s why we’re hard at work developing novel treatments that deliver groundbreaking science exactly where patients need it — their skin. Dermavant launched its first product, VTAMA® (tapinarof) cream, 1%, for the topical treatment of plaque psoriasis in adults in 2022. Dermavant is also developing VTAMA cream for the treatment of atopic dermatitis in adults and children as young as 2 years old. At Dermavant we have a passion for science and a commitment to Dermatology, that’s why we are developing innovative treatments that meet physicians’ and patient’s needs. Because skin is more than superficial – it’s where we live, every moment of every day.